Stock 512 GRAND PHARMACEUTICAL GROUP LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Grand Pharmaceutical Group Limited

Equities

512

BMG210A71016

Pharmaceuticals

Delayed Hong Kong S.E.
Other stock markets
 10:49:56 2024-04-28 pm EDT 		5-day change 1st Jan Change
4.38 HKD +1.39% Intraday chart for Grand Pharmaceutical Group Limited +9.77% +7.09%
Mar. 27 Grand Pharmaceutical Group Limited Enters into Strategic Cooperation Agreement for Product Introduction with LianBio Development (HK) Limited and Tarsus Pharmaceuticals, Inc CI
Mar. 25 Grand Pharma Receives Green Light for Phase III Trials of Cancer Drug MT

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 11,223 14,321 24,421 22,930 16,225 15,128 15,128 -
Enterprise Value (EV) 1 11,223 14,321 24,421 22,930 16,225 14,394 15,128 15,128
P/E ratio - - - - - 7.63 x 6.26 x 5.4 x
Yield - - - - 3.04% 6.36% 3.01% 3.7%
Capitalization / Revenue 1.88 x 2.17 x 3.84 x 2.67 x 1.7 x 1.37 x 1.25 x 1.11 x
EV / Revenue 1.88 x 2.17 x 3.84 x 2.67 x 1.7 x 1.37 x 1.25 x 1.11 x
EV / EBITDA - - 10,116,064 x 7,124,918 x - - - -
EV / FCF - - - 14.9 x 13.3 x 6.53 x 9.18 x 7.36 x
FCF Yield - - - 6.69% 7.5% 15.3% 10.9% 13.6%
Price to Book - - - 1.71 x 1.14 x 0.94 x 0.86 x 0.76 x
Nbr of stocks (in thousands) 3,134,826 3,377,571 3,549,571 3,549,571 3,527,141 3,501,810 3,501,810 -
Reference price 2 3.580 4.240 6.880 6.460 4.600 4.320 4.320 4.320
Announcement Date 3/26/19 3/27/20 4/28/21 3/17/22 3/22/23 3/19/24 - -
1HKD in Million2HKD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net sales 1 5,958 6,591 6,353 8,598 9,562 10,530 12,055 13,620
EBITDA - - 2,414 3,218 - - - -
EBIT 1 - 1,383 2,127 2,879 2,654 2,549 3,205 3,681
Operating Margin - 20.98% 33.48% 33.48% 27.76% 24.21% 26.59% 27.03%
Earnings before Tax (EBT) 1 - - - - - 2,344 2,988 3,463
Net income 1 - - - - - 1,880 2,445 2,835
Net margin - - - - - 17.85% 20.28% 20.81%
EPS 2 - - - - - 0.5360 0.6900 0.8000
Free Cash Flow 1 - - - 1,534 1,216 2,317 1,648 2,056
FCF margin - - - 17.84% 12.72% 21.85% 13.67% 15.1%
FCF Conversion (EBITDA) - - - 47.67% - - - -
FCF Conversion (Net income) - - - - - 109.04% 67.4% 72.52%
Dividend per Share 2 - - - - 0.1400 0.2600 0.1300 0.1600
Announcement Date 3/26/19 3/27/20 4/28/21 3/17/22 3/22/23 3/19/24 - -
1HKD in Million2HKD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - - - 1,534 1,216 2,317 1,648 2,056
ROE (net income / shareholders' equity) - - 18.3% 19.5% 15.1% 12.8% 14% 14%
ROA (Net income/ Total Assets) - - 11.6% 12.6% - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 - - - 3.770 4.020 4.330 5.030 5.670
Cash Flow per Share - - - - - - - -
Capex 1 373 566 209 472 626 600 800 1,000
Capex / Sales 6.26% 8.59% 3.29% 5.48% 6.55% 5.66% 6.64% 7.34%
Announcement Date 3/26/19 3/27/20 4/28/21 3/17/22 3/22/23 3/19/24 - -
1HKD in Million2HKD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.32
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
GRAND PHARMACEUTICAL GROUP LIMITED Stock Grand Pharmaceutical Group Limited
+7.09% 1.93B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 512 Stock
  4. Financials Grand Pharmaceutical Group Limited